Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 17/20 | 0.63 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.59 |
| ▸ | HAVCR2 | Q8TDQ0 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | HTR3A | P46098 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14828939 | 0.78 | HRH4 (1.00) | HRH4HRH3HTR3A | |
| SCHEMBL20859214 | 0.76 | HRH4 (0.87) | HRH4HRH3HTR3A | |
| SCHEMBL14828845 | 0.75 | HRH3 (1.00) | HRH4HRH3HTR3A | |
| SCHEMBL406515 | 0.74 | CUL4A (0.57) | HRH4HAVCR2HTT | |
| SCHEMBL14828859 | 0.73 | HRH4 (0.64) | HRH4HRH3HAVCR2HSD17B10 | |
| SCHEMBL14829085 | 0.71 | HRH3 (0.46) | HRH4HRH3HAVCR2 | |
| SCHEMBL14828786 | 0.71 | HRH3 (0.66) | HRH4HRH3HTR3A | |
| SCHEMBL14829006 | 0.71 | HRH4 (0.62) | HRH4HRH3HAVCR2HSD17B10 | |
| SCHEMBL14829055 | 0.65 | HRH4 (1.00) | HRH4HRH3HAVCR2HTR3A | |
| SCHEMBL14828886 | 0.65 | HRH4 (1.00) | HRH4HRH3HAVCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3461825-A1 | NOVEL HETEROCYCLIC DERIVATIVES AND THEIR USES | C&C Research Laboratories (KR) | 2019-04-03 | — | — | EP | disclosed |
| EP-2760865-B1 | NOVEL HETEROCYCLIC DERIVATIVES AND THEIR USES | C&C RES LAB (KR) | 2018-07-11 | — | — | EP | disclosed |
| US-9586959-B2 | Substituted tricyclic heterocycles as histamine 4 receptor inhibitors | C&C RESEARCH LABORATORIES (KR) | 2017-03-07 | — | — | US | disclosed |
| US-20140315888-A1 | NOVEL HETEROCYCLIC DERIVATIVES AND THEIR USES | C&C RESEARCH LABORATORIES (KR) | 2014-10-23 | — | — | US | disclosed |
| EP-2760865-A2 | NOVEL HETEROCYCLIC DERIVATIVES AND THEIR USES | C&C Research Laboratories (KR) | 2014-08-06 | — | — | EP | disclosed |
| WO-2013048214-A2 | NOVEL HETEROCYCLIC DERIVATIVES AND THEIR USES | C&C RESEARCH LABORATORIES (KR) | 2013-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140315888-A1 | NOVEL HETEROCYCLIC DERIVATIVES AND THEIR USES | HRH4, HRH2, HRH1 | HRH4 1/4885HRH3 4/4885HAVCR2 409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.